Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Tiffany T. Montellano"'
Autor:
Kader Yagiz, Maria E. Rodriguez-Aguirre, Fernando Lopez Espinoza, Tiffany T. Montellano, Daniel Mendoza, Leah A. Mitchell, Carlos E. Ibanez, Noriyuki Kasahara, Harry E. Gruber, Douglas J. Jolly, Joan M. Robbins
Publikováno v:
Molecular Therapy: Oncolytics, Vol 8, Iss , Pp 14-26 (2018)
Treatment of tumors with Toca 511, a gamma retroviral replicating vector encoding cytosine deaminase, followed by 5-fluorocytosine (5-FC) kills tumors by local production of 5-fluorouracil (5-FU). In brain tumor models, this treatment induces systemi
Externí odkaz:
https://doaj.org/article/6ac8a40fe95149c799cb30f64a45ae08
Autor:
Michael A. Vogelbaum, Yaron A. Moshel, Jay-Jiguang Zhu, Tobias Walbert, Michael Salacz, William P. Accomando, Dimitris G. Placantonakis, Kevin Petrecca, Aliz R. Rao, Fairooz F. Kabbinavar, Derek Ostertag, Lyndon Kim, Fabio M. Iwamoto, Steven Brem, Chetan Bettegowda, James Perry, Clark C. Chen, Nicholas Butowski, Joseph Landolfi, David Piccioni, Daniela A. Bota, Daniel J. Hogan, David Cachia, Tiffany T. Montellano, Thian Kheoh, Timothy F. Cloughesy, George J. Kaptain, Harry E. Gruber, Brad Elder, Denise Damek
Publikováno v:
JAMA oncology, vol 6, iss 12
JAMA Oncol
JAMA Oncol
Importance New treatments are needed to improve the prognosis of patients with recurrent high-grade glioma. Objective To compare overall survival for patients receiving tumor resection followed by vocimagene amiretrorepvec (Toca 511) with flucytosine
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7ce24ce6c4cbe1005077e7cb8405c5b7
https://escholarship.org/uc/item/85t6k5t9
https://escholarship.org/uc/item/85t6k5t9
Autor:
Harry E. Gruber, Tiffany T. Montellano, Oscar Diago, Derek Ostertag, Dawn Gammon, Asha M. Das, William P. Accomando, Ali Haghighi, Douglas J. Jolly, Leah Mitchell, Daniel J. Hogan
Publikováno v:
Molecular Cancer Therapeutics. 17:B010-B010
Toca 511 (vocimagene amiretrorepvec), in combination with Toca FC (5-FC; flucytosine extended-release tablets), is an investigational combination product currently under development for the treatment of high-grade glioma (HGG) and other solid tumors.